When circulating tumor DNA (ctDNA) of the peripheral blood was analyzed, HER2 somatic mutations were detected in 8.9% of metastatic breast cancer patients and they were associated with shorter progression-free survival (PFS) (46). The gene discussed is ERBB2; the disease is neoplasm.